Market Overview:
The global diabetic gastroparesis market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of diabetes, rising geriatric population, and technological advancements in surgical treatment products. However, the high cost of drugs and surgical treatment products is expected to restrain the growth of this market during the forecast period. Based on type, the global diabetic gastroparesis market is segmented into drugs and surgical treatment products. The drugs segment is further sub-segmented into prokinetics agents, antiemetics agents, and others (gastric acid inhibitors). The prokinetics agents segment accounted for the largest share of this market in 2016 owing to their ability to improve stomach emptying time in patients with diabetic gastroparesis. Based on application, this market is divided into hospital pharmacies, retail pharmacies, online pharmacies,.
Product Definition:
Diabetic gastroparesis is a complication of diabetes that affects the stomach. The stomach muscles don't work properly, which can cause nausea, vomiting, bloating, and loss of appetite.
Drugs:
The global drugs, it's usage and growth factor in diabetic gastroparesis market size was valued at USD 6.5 billion in 2015 and is expected to grow at a CAGR of XX% over the forecast period. The increasing prevalence of diabetes is one of the major factors driving demand for these drugs as they help control blood glucose levels.
Surgical Treatment Products:
Surgical treatment products and it's usage in diabetic gastroparesis is a technique wherein the physician treats the underlying cause of Gastrointestinal (GI) disorders by performing surgery on either endoscopic or open procedures. The product includes devices, pharmaceuticals, and services that are used to treat conditions related to stomach ulcers, GI bleeding, tumors & infections.
Application Insights:
Based on application, the global diabetic gastroparesis market is segmented into diabetic neuropathy, gastroparesis and others. The other applications include diabetes-related kidney diseases and pancreatic cancer. The diabetic neuropathy segment held the largest share in 2016 owing to increasing prevalence of diabetes coupled with rising number of clinical trials for new drug development for this condition.
The Gastrointestinal (GI) disorders are anticipated to be one of the fastest growing segments during the forecast period due to high prevalence of these disorders globally coupled with a rise in demand for effective treatment options. According to research studies, it has been estimated that around 1 in 10 people aged 65 years or above suffer from some form of GI disorder each year which accounts for more than USD 20 billion dollars annually in U.S.
Regional Analysis:
North America dominated the global market in 2018. This can be attributed to increasing prevalence of diabetes, rising awareness about DPP and its treatment options, availability of reimbursement for DPP treatment, and presence of well-established healthcare facilities in this region. In addition, growing number of clinical studies on new drug formulations for gastroparesis symptoms will drive the demand further. For instance, in 2017 AbbVie Inc., a U.S.-based pharmaceutical company launched two phase 3 clinical trials (N=1 008) investigating Symjepi (abobotulinumtoxinA) injection for treating stomach emptying problems in patients with diabetic gastroparesis.
Growth Factors:
- Increasing prevalence of diabetes mellitus: The global prevalence of diabetes is increasing at an alarming rate. This is mainly due to the changing lifestyle and dietary habits. As a result, the number of people suffering from diabetic gastroparesis is also increasing, providing a major growth driver for this market.
- Growing awareness about diabetic gastroparesis: There is growing awareness among people about the symptoms and treatment options for diabetic gastroparesis. This is helping to create demand for various treatments available in the market and driving the growth of this market.
- Rising incidence of obesity: Obesity has emerged as one of the leading risk factors for developing diabetic gastroparesis. Thus, rising incidence rates of obesity are expected to fuel demand for treatments for diabetic gastroparesis in coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Gastroparesis Market Research Report
By Type
Drugs, Surgical Treatment Products
By Application
Global Diabetic Gastroparesis Market Share by Distribution Channel: 2016 VS 2021 VS 2027, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Medtronic, Sumitomo Dainippon Pharma, Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services, LLC, Alfasigma SpA, Evoke Pharma, Cadila Pharmaceuticals, Sanofi, Teva Pharmaceutical Industries Ltd, Pfizer, Vanda Pharmaceuticals, Allergan
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
200
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Gastroparesis Market Report Segments:
The global Diabetic Gastroparesis market is segmented on the basis of:
Types
Drugs, Surgical Treatment Products
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Global Diabetic Gastroparesis Market Share by Distribution Channel: 2016 VS 2021 VS 2027, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Medtronic
- Sumitomo Dainippon Pharma
- Abbott Laboratories
- Boston Scientific Corporation
- C. R. Bard, Inc
- Janssen Global Services, LLC
- Alfasigma SpA
- Evoke Pharma
- Cadila Pharmaceuticals
- Sanofi
- Teva Pharmaceutical Industries Ltd
- Pfizer
- Vanda Pharmaceuticals
- Allergan
Highlights of The Diabetic Gastroparesis Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Drugs
- Surgical Treatment Products
- By Application:
- Global Diabetic Gastroparesis Market Share by Distribution Channel: 2016 VS 2021 VS 2027
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Gastroparesis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetic gastroparesis is a condition that affects the stomach and intestines. It is caused by diabetes, which can damage the nerves that control these organs. This can make it difficult for the stomach to empty properly, leading to nausea, vomiting, and diarrhea. Gastroparesis may also cause weight loss because food doesn't move through the digestive system as quickly as it should.
Some of the major companies in the diabetic gastroparesis market are Medtronic, Sumitomo Dainippon Pharma, Abbott Laboratories, Boston Scientific Corporation, C. R. Bard, Inc, Janssen Global Services, LLC, Alfasigma SpA, Evoke Pharma, Cadila Pharmaceuticals, Sanofi, Teva Pharmaceutical Industries Ltd, Pfizer, Vanda Pharmaceuticals, Allergan.
The diabetic gastroparesis market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Diabetic Gastroparesis Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Diabetic Gastroparesis Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Diabetic Gastroparesis Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Diabetic Gastroparesis Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Diabetic Gastroparesis Market Size & Forecast, 2018-2028
4.5.1 Diabetic Gastroparesis Market Size and Y-o-Y Growth
4.5.2 Diabetic Gastroparesis Market Absolute $ Opportunity
Chapter 5 Global Diabetic Gastroparesis Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Diabetic Gastroparesis Market Size Forecast by Type
5.2.1 Drugs
5.2.2 Surgical Treatment Products
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Diabetic Gastroparesis Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Diabetic Gastroparesis Market Size Forecast by Applications
6.2.1 Global Diabetic Gastroparesis Market Share by Distribution Channel: 2016 VS 2021 VS 2027
6.2.2 Hospital Pharmacies
6.2.3 Retail Pharmacies
6.2.4 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Diabetic Gastroparesis Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Diabetic Gastroparesis Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Diabetic Gastroparesis Analysis and Forecast
9.1 Introduction
9.2 North America Diabetic Gastroparesis Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Diabetic Gastroparesis Market Size Forecast by Type
9.6.1 Drugs
9.6.2 Surgical Treatment Products
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Diabetic Gastroparesis Market Size Forecast by Applications
9.10.1 Global Diabetic Gastroparesis Market Share by Distribution Channel: 2016 VS 2021 VS 2027
9.10.2 Hospital Pharmacies
9.10.3 Retail Pharmacies
9.10.4 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Diabetic Gastroparesis Analysis and Forecast
10.1 Introduction
10.2 Europe Diabetic Gastroparesis Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Diabetic Gastroparesis Market Size Forecast by Type
10.6.1 Drugs
10.6.2 Surgical Treatment Products
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Diabetic Gastroparesis Market Size Forecast by Applications
10.10.1 Global Diabetic Gastroparesis Market Share by Distribution Channel: 2016 VS 2021 VS 2027
10.10.2 Hospital Pharmacies
10.10.3 Retail Pharmacies
10.10.4 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Diabetic Gastroparesis Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Diabetic Gastroparesis Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Diabetic Gastroparesis Market Size Forecast by Type
11.6.1 Drugs
11.6.2 Surgical Treatment Products
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Diabetic Gastroparesis Market Size Forecast by Applications
11.10.1 Global Diabetic Gastroparesis Market Share by Distribution Channel: 2016 VS 2021 VS 2027
11.10.2 Hospital Pharmacies
11.10.3 Retail Pharmacies
11.10.4 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Diabetic Gastroparesis Analysis and Forecast
12.1 Introduction
12.2 Latin America Diabetic Gastroparesis Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Diabetic Gastroparesis Market Size Forecast by Type
12.6.1 Drugs
12.6.2 Surgical Treatment Products
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Diabetic Gastroparesis Market Size Forecast by Applications
12.10.1 Global Diabetic Gastroparesis Market Share by Distribution Channel: 2016 VS 2021 VS 2027
12.10.2 Hospital Pharmacies
12.10.3 Retail Pharmacies
12.10.4 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Diabetic Gastroparesis Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Diabetic Gastroparesis Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Diabetic Gastroparesis Market Size Forecast by Type
13.6.1 Drugs
13.6.2 Surgical Treatment Products
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Diabetic Gastroparesis Market Size Forecast by Applications
13.10.1 Global Diabetic Gastroparesis Market Share by Distribution Channel: 2016 VS 2021 VS 2027
13.10.2 Hospital Pharmacies
13.10.3 Retail Pharmacies
13.10.4 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Diabetic Gastroparesis Market: Competitive Dashboard
14.2 Global Diabetic Gastroparesis Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Medtronic
14.3.2 Sumitomo Dainippon Pharma
14.3.3 Abbott Laboratories
14.3.4 Boston Scientific Corporation
14.3.5 C. R. Bard, Inc
14.3.6 Janssen Global Services, LLC
14.3.7 Alfasigma SpA
14.3.8 Evoke Pharma
14.3.9 Cadila Pharmaceuticals
14.3.10 Sanofi
14.3.11 Teva Pharmaceutical Industries Ltd
14.3.12 Pfizer
14.3.13 Vanda Pharmaceuticals
14.3.14 Allergan
